{"classes":[{"categories":[{"measurements":[{"comment":"Median DR and upper limit of Confidence Interval not estimable due to insufficient number of participants with event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median DR and upper limit of Confidence Interval not estimable due to insufficient number of participants with event.","groupId":"OG001","lowerLimit":"30.1","upperLimit":"NA","value":"NA"},{"comment":"Median DR and upper limit of Confidence Interval not estimable due to insufficient number of participants with event.","groupId":"OG002","lowerLimit":"16.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"DR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. CR: disappearance of all lesions; any pathological lymph nodes (target lesions \\[TLs\\]) or non-target lesions (non-TLs) must have reduction in short axis to \\<10 mm; normalization of tumor marker level for non-TLs; PR: \\>=30% decrease in sum of diameter of all TLs, taking as reference baseline sum of diameters; DR (in weeks) was calculated as (first date of PD or death - first date of CR or PR +1)/7. The median DR was estimated using Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"In ALK genetic event positive participants with ALCL, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG000","title":"ALCL Arm"},{"description":"In ALK genetic event positive participants with IMT, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG001","title":"IMT Arm"},{"description":"In ALK genetic event positive participants with other tumors (excluding non-small cell lung cancer), crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG002","title":"Other Tumors"}],"paramType":"MEDIAN","populationDescription":"Participants enrolled and treated who had baseline tumor assessment result and had confirmed CR or PR.","reportingStatus":"POSTED","timeFrame":"From the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first (maximum 374 weeks)","title":"Duration of Response (DR) Based on Investigator Assessement","type":"SECONDARY","unitOfMeasure":"Weeks"}